JP7699378B2 - 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法 - Google Patents

軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法 Download PDF

Info

Publication number
JP7699378B2
JP7699378B2 JP2021514303A JP2021514303A JP7699378B2 JP 7699378 B2 JP7699378 B2 JP 7699378B2 JP 2021514303 A JP2021514303 A JP 2021514303A JP 2021514303 A JP2021514303 A JP 2021514303A JP 7699378 B2 JP7699378 B2 JP 7699378B2
Authority
JP
Japan
Prior art keywords
cyclic
disease
cpg
prolylglycine
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021514303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524864A (ja
JP2021524864A5 (https=
Inventor
ハン ロイ トラン ロイド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lloyd Hung Loi Tran
Original Assignee
Lloyd Hung Loi Tran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lloyd Hung Loi Tran filed Critical Lloyd Hung Loi Tran
Publication of JP2021524864A publication Critical patent/JP2021524864A/ja
Publication of JP2021524864A5 publication Critical patent/JP2021524864A5/ja
Priority to JP2025014460A priority Critical patent/JP2025084741A/ja
Application granted granted Critical
Publication of JP7699378B2 publication Critical patent/JP7699378B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021514303A 2018-05-15 2019-05-15 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法 Active JP7699378B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014460A JP2025084741A (ja) 2018-05-15 2025-01-31 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862671485P 2018-05-15 2018-05-15
US201862671466P 2018-05-15 2018-05-15
US62/671,466 2018-05-15
US62/671,485 2018-05-15
US201862674855P 2018-05-22 2018-05-22
US62/674,855 2018-05-22
PCT/US2019/032403 WO2019222339A1 (en) 2018-05-15 2019-05-15 Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014460A Division JP2025084741A (ja) 2018-05-15 2025-01-31 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2021524864A JP2021524864A (ja) 2021-09-16
JP2021524864A5 JP2021524864A5 (https=) 2022-11-02
JP7699378B2 true JP7699378B2 (ja) 2025-06-27

Family

ID=68541027

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514303A Active JP7699378B2 (ja) 2018-05-15 2019-05-15 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法
JP2025014460A Pending JP2025084741A (ja) 2018-05-15 2025-01-31 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014460A Pending JP2025084741A (ja) 2018-05-15 2025-01-31 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法

Country Status (9)

Country Link
US (3) US11090303B2 (https=)
EP (1) EP3843768A4 (https=)
JP (2) JP7699378B2 (https=)
CN (1) CN112423774A (https=)
AU (1) AU2019271189A1 (https=)
BR (1) BR112020023252A2 (https=)
GB (1) GB202015788D0 (https=)
MA (1) MA53500A (https=)
WO (1) WO2019222339A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240398792A1 (en) * 2018-05-15 2024-12-05 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
EP3843768A4 (en) * 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS
GB2613460B (en) * 2020-04-20 2025-07-23 Lloyd Hung Loi Tran Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a
WO2022051631A1 (en) * 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
TW202245773A (zh) * 2021-02-12 2022-12-01 紐西蘭商紐藍製藥公司 普威二氏症候群之治療
CN114582507A (zh) * 2022-03-04 2022-06-03 青海省畜牧兽医科学院 基于地理探测器的泡型包虫病环境风险因子分析方法
KR20260049797A (ko) * 2023-07-12 2026-04-14 로이드 트란 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis
WO2025160184A1 (en) * 2024-01-23 2025-07-31 Lloyd Tran Methods for the prophylaxis and treatment of obesity and related conditions and disorders
WO2025179250A1 (en) * 2024-02-25 2025-08-28 Lloyd Tran Methods for the prophylaxis and treatment of autism related disorders
WO2025198995A1 (en) * 2024-03-18 2025-09-25 Lloyd Tran Methods for the prophylaxis and treatment of stroke related disorders
CN119770491B (zh) * 2024-12-20 2025-10-17 北京大学 环甘氨酸-脯氨酸在制备治疗暴食症的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258663A1 (en) 2003-09-03 2006-11-16 Neuren Pharmaceuticals Limited Cyclic G-2AllylProline in treatment of Parkinson's disease
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US20150306171A1 (en) 2001-11-13 2015-10-29 Lloyd Hung Loi Tran Therapeutic agent composition and method of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2670563B2 (ja) 1988-10-12 1997-10-29 富士通株式会社 半導体装置の製造方法
JP2757960B2 (ja) 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
WO1995017204A1 (en) 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5942422A (en) 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6187906B1 (en) 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
PT1064256E (pt) 1998-03-17 2004-10-29 Pfizer Prod Inc Biciclo[2.2.1] heptanos e compostos relacionados
US6258582B1 (en) 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
AU781044B2 (en) 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
US6689904B2 (en) 2001-06-29 2004-02-10 Wyeth Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
CA2466701C (en) * 2001-11-13 2013-11-12 Loi Tran Neuroprotective use of cyclic prolyl glycine
US20050209142A1 (en) * 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
WO2015013397A2 (en) * 2013-07-25 2015-01-29 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
JP2021514303A (ja) * 2018-02-19 2021-06-10 ザ マテリアル ワークス，リミテッド 金属薄板デスケーラのための幅及び速度コントロールならびにそれを使用する方法
EP3843768A4 (en) 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US20150306171A1 (en) 2001-11-13 2015-10-29 Lloyd Hung Loi Tran Therapeutic agent composition and method of use
US20060258663A1 (en) 2003-09-03 2006-11-16 Neuren Pharmaceuticals Limited Cyclic G-2AllylProline in treatment of Parkinson's disease

Also Published As

Publication number Publication date
WO2019222339A1 (en) 2019-11-21
EP3843768A4 (en) 2022-11-23
US12070458B2 (en) 2024-08-27
BR112020023252A2 (pt) 2021-02-23
JP2021524864A (ja) 2021-09-16
EP3843768A1 (en) 2021-07-07
GB202015788D0 (en) 2020-11-18
CN112423774A (zh) 2021-02-26
US20200054629A1 (en) 2020-02-20
AU2019271189A1 (en) 2021-01-07
US11090303B2 (en) 2021-08-17
MA53500A (fr) 2021-08-18
US20220000866A1 (en) 2022-01-06
US20230381175A1 (en) 2023-11-30
JP2025084741A (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
JP7699378B2 (ja) 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法
Plosker et al. Cerebrolysin: a review of its use in dementia
US20100178277A1 (en) Methods and compositions for stimulating cells
US20150306171A1 (en) Therapeutic agent composition and method of use
Lei et al. Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway
JP4943847B2 (ja) 抗分泌性因子の新規の使用
US20120142604A1 (en) Novel applications of hip/pap or derivatives thereof
Zhang et al. Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson’s disease
JP2025186333A (ja) 三次元スフェロイド型細胞凝集体に由来の細胞外小胞を含む神経再生促進組成物
JP2005514406A (ja) 疾患および損傷の処置のための一酸化窒素ドナー
US20030109531A1 (en) Therapeutic agent composition and method of use
Xiong et al. Effect of sutellarin on neurogenesis in neonatal hypoxia–ischemia rat model: potential mechanisms of action
WO2016125330A1 (ja) 網膜再生促進薬
JP2022552217A (ja) 脊髄損傷の治療のため及び／又は髄鞘再形成のためのペプチドの全身投与
US20240398792A1 (en) Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
CA2466701A1 (en) Neuroprotective use of cyclic prolyl glycine
JP6397122B2 (ja) 血管新生関連疾患を治療するためのペプチドの使用
CN102813914A (zh) 一种用于治疗或预防脑血管及相关疾病的药物组合物
KR20260049797A (ko) 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
EP1109887A1 (en) Production and use of dopaminergic cells to treat dopaminergic deficiencies
WO2025198995A1 (en) Methods for the prophylaxis and treatment of stroke related disorders
RU2744453C2 (ru) Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний
WO2025179250A1 (en) Methods for the prophylaxis and treatment of autism related disorders
CN121588114A (zh) 巴多昔芬在制备用于促进脊髓损伤后的运动功能恢复的药物中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20220627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250610

R150 Certificate of patent or registration of utility model

Ref document number: 7699378

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150